Cathie Wood's ARK funds made just one trade on Thursday, adding 56,769 shares of Intellia Therapeutics across ARKK and ARKG. The CRISPR-focused biotech is up more than 30% year-to-date and is heading for its best week since October. Despite prior setbacks in 2025, ARK continues to build conviction in the gene-editing firm.